Pharma shift
The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…
Investing in Cambridge drug discovery
PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…
Biotech vs big pharma
Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…
Manhattan Project?
A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…
Drug trials
An Executive MBA alumnus, Dr Rav Seeruthun, heads a Roche team that has developed a drug being tested to fight COVID-19. Dr Rav Seeruthun (EMBA 2013) of Cambridge Judge Business School, is heading a team at the Roche UK Medical Directorate that has developed…
Fast Company: How open-source medicine could prepare us for the next pandemic
A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had…
Pharma Voice: New pipeline pathways
Repurposing existing drugs could reduce cost and time when developing new medicine, but it’s not a straightforward approach. According to a study by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge, only two per cent of new…
Funding for rare diseases startup
Healx, a company that seeks breakthroughs for rare diseases through artificial intelligence, said it had secured $56 million in Series B financing, led by venture capital firm Atomico and joined by Intel Capital, Global Brain and btov Partners. All previous investors…
Pharma journey
From Greece to Scotland Yard to providing drugs for clinical trials: Cambridge MBA alumna Vanessa Dekou (MBA 2002) built a global pharma business from scratch. Vanessa Dekou Cambridge MBA alumnus Vanessa Dekou re-mortgaged her London house to set up her…
Healthcare policy & drug development (The Cambridge Judge Business Debate podcast series)
How ageing societies can afford healthcare for all and reform an organisational system that has not kept pace with technology. L-R: Paul Tracey, Michael Kitson, Kamal Munir, Stefan Scholtes, Nektarios Oraiopoulos In this episode, joining podcast host Michael Kitson, University…
